慢性阻塞性肺疾病患者应用福多司坦胶囊联合布地格福吸入气雾剂治疗的效果及安全性分析  

Efficacy and Safety Analysis of Fodosteine Capsules Combined with Budesonide,Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol in Patients with Chronic Obstructive Pulmonary Disease

作　　者：李忠义 李秋忠 苏杭 李建武 LI Zhongyi;LI Qiuzhong;SU Hang;LI Jianwu(Hebi People's Hospital,Hebi Henan 458030,China)

机构地区：[1]鹤壁市人民医院,河南鹤壁458030

出　　处：《药品评价》2024年第10期1282-1285,共4页Drug Evaluation

摘　　要：目的探究福多司坦胶囊与布地格福吸入气雾剂联合治疗慢性阻塞性肺疾病(COPD)的应用价值。方法选取2022年1月至2024年1月鹤壁市人民医院120例COPD患者,采用简单随机法分为对照1组(n=40)、对照2组(n=40)、联合组(n=40)。三组患者均给予常规治疗,对照1组给予布地格福吸入气雾剂治疗,对照2组给予福多司坦胶囊治疗,联合组采用福多司坦胶囊与布地格福吸入气雾剂联合治疗,治疗时间为3个月。对比三组治疗效果;治疗前与治疗3个月后氧化应激指标[超氧化物歧化酶(SOD)、过氧化氢酶(CAT)、活性氧(ROS)],肺功能[第1秒用力呼气容积/用力肺活量(FEV_(1)/FVC)、FVC、呼气峰流速(PEF)]及生活质量;观察治疗期间不良反应情况。结果联合组治疗有效率高于对照1组和对照2组(P<0.05)。治疗3个月后,联合组SOD、CAT高于对照1组和对照2组,ROS低于对照1组和对照2组(P<0.05);联合组FVC、FEV_(1)/FVC、PEF高于对照1组和对照2组(P<0.05);联合组慢性阻塞性肺疾病评估测试(CAT)评分低于对照1组和对照2组,日常生活活动能力评分高于对照1组和对照2组(P<0.05)。三组不良反应发生率差异无统计学意义(P>0.05)。结论福多司坦胶囊联合布地格福吸入气雾剂治疗COPD患者效果显著,能减轻氧化应激,改善肺功能,提高患者预后,且安全性较高。Objective To explore the application value of fodosteine capsules and budesonide,glycopyrronium bromide and formoterol fumarate inhalation aerosol(BGBFF)in the treatment of chronic obstructive pulmonary disease(COPD).Methods A total of 120 patients with COPD in Hebi People's Hospital from January 2022 to January 2024 were selected and divided into control group 1(n=40),control group 2(n=40)and combination group(n=40)by simple random method.All patients in the 3 groups were given conventional treatment,control group 1 was given BGBFF treatment,control group 2 was given fodosteine capsules treatment,combination group was given fodosteine capsules and BGBFF treatment,treatment time was 3 months.The therapeutic effect,oxidative stress index[superoxide dismutase(SOD),catalase(CAT),reactive oxygen species(ROS)],lung function[forced expiratory volume in the first second/forced vital capacity(FEV_(1)/FVC),FVC,peak expiratory flow rate(PEF)]and quality of life of the 3 groups were compared before treatment and after treatment.The adverse reactions were observed during treatment.Results The effective rate of combination group was higher than that of control group 1 and control group 2(P<0.05).After 3 months of treatment,SOD and CAT in combination group were higher than those in control group 1 and control group 2,and ROS were lower than those in control group 1 and control group 2(P<0.05);FVC,FEV_(1)/FVC and PEF in combination group were higher than those in control group 1 and control group 2(P<0.05);the CAT score of combination group was lower than that of control group 1 and control group 2,and the ADL score was higher than that of control group 1 and control group 2(P<0.05).There was no significant difference in the incidence of adverse reactions among the three groups(P>0.05).Conclusion Fodosteine capsules combined with budesonide,glycopyrronium bromide and formoterol fumarate inhalation aerosol is effective in the treatment of COPD patients,which can reduce oxidative stress,improve lung function,and improve the progn

关 键 词：慢性阻塞性肺疾病 布地格福吸入气雾剂 福多司坦胶囊 肺功能 氧化应激 不良反应 

分 类 号：R563.9[医药卫生—呼吸系统]